AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29661218 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced follow-up schedule (4 visits over 3 years)
Number of subjects: 282
Study 29661218 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up schedule (10-13 visits over 5 years)
Number of subjects: 282
Study 28460629 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg plus Ezetimibe 10 mg daily
Number of subjects: 4650
Study 28460629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4650
Study 26631004 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion
Number of subjects: 143
Study 26631004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 26631004 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GIK and placebo
Number of subjects: 143
Study 26631004 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP measured at 12 hours
Number of subjects: 143
Study 23332608 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based intervention (cognitive behavioral therapy, psychotropic medication or both)
Number of subjects: 1004
Study 23332608 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1004
Study 21734163 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterfactual seeking (choice to learn about foregone alternatives)
Number of subjects: 0
Study 21734163 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginative thoughts about foregone options
Number of subjects: 0
Study 21734163 — intervention group
Group type: EXPERIMENTAL
Intervention: Upward counterfactual thoughts
Number of subjects: 0
Study 18926434 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan (20 mg loading dose followed by 2 successive 24-hour continuous infusions of 40, 80, or 120 mg/d)
Number of subjects: 170
Study 18926434 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan 40 mg/d
Number of subjects: 170
Study 18926434 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan 80 mg/d
Number of subjects: 170
Study 18926434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 16292517 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery group (LSG)
Number of subjects: 40
Study 16292517 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery group (CSG)
Number of subjects: 40
Study 12754014 — intervention group
Group type: EXPERIMENTAL
Intervention: Total arterial revascularization (Group 1)
Number of subjects: 188
Study 12754014 — intervention group
Group type: COMPARATOR
Intervention: Standard CABG (Group 2)
Number of subjects: 188
Study 11005229 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral image analysis using the SpectraCube system for evaluating ER content.
Number of subjects: 13
Study 11005229 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral image analysis for ER detection in cases scored as 0 by the pathologist's index.
Number of subjects: 13
Study 11005229 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral image analysis in a test case scored as 1 by the pathologist's index.
Number of subjects: 13
Study 8973993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 5 mg
Number of subjects: 9
Study 8973993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 10 mg
Number of subjects: 9
Study 8973993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 20 mg
Number of subjects: 9
Study 8973993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1456384 — intervention group
Group type: EXPERIMENTAL
Intervention: New slow-release preparation of valproic acid (SR-VPA)
Number of subjects: 13
Study 1456384 — intervention group
Group type: COMPARATOR
Intervention: Conventional preparation of valproic acid (C-VPA)
Number of subjects: 13
Study 4074116 — intervention group
Group type: EXPERIMENTAL
Intervention: 1cm lift under left or right foot
Number of subjects: 14
Study 4074116 — intervention group
Group type: EXPERIMENTAL
Intervention: 2cm lift under left or right foot
Number of subjects: 14
Study 4074116 — intervention group
Group type: EXPERIMENTAL
Intervention: 3cm lift under left or right foot
Number of subjects: 14
Study 4074116 — intervention group
Group type: EXPERIMENTAL
Intervention: 4cm lift under left or right foot
Number of subjects: 14
Study 4074116 — intervention group
Group type: COMPARATOR
Intervention: Barefoot condition (no lifts)
Number of subjects: 14
Study 30820005 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hemodialysis
Number of subjects: 919
Study 30820005 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose hemodialysis
Number of subjects: 919
Study 30820005 — intervention group
Group type: EXPERIMENTAL
Intervention: High flux hemodialysis
Number of subjects: 919
Study 30820005 — intervention group
Group type: COMPARATOR
Intervention: Low flux hemodialysis
Number of subjects: 919
Study 30820005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stable FGF23 trajectory
Number of subjects: 919
Study 30820005 — intervention group
Group type: COMPARATOR
Intervention: Elevated stable FGF23 trajectory
Number of subjects: 919
Study 29630570 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Active Motion (CAM) therapy
Number of subjects: 50
Study 29630570 — intervention group
Group type: COMPARATOR
Intervention: Continuous Passive Motion (CPM) therapy
Number of subjects: 50
Study 26352863 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (1 or 3 mg nightly)
Number of subjects: 81
Study 26352863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 25130678 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20mg/d)
Number of subjects: 60
Study 25130678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22787067 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose polycap (plus K(+) supplementation)
Number of subjects: 518
Study 22787067 — intervention group
Group type: COMPARATOR
Intervention: Low-dose polycap
Number of subjects: 518
Study 20150769 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy
Number of subjects: 128
Study 20150769 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy plus radiotherapy
Number of subjects: 128
Study 20150769 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclin 1 high expression
Number of subjects: 128
Study 20150769 — intervention group
Group type: EXPERIMENTAL
Intervention: HIF-1alpha expression
Number of subjects: 128
Study 17846268 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b, 250 microg subcutaneously every other day
Number of subjects: 404
Study 15316509 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin sodium (5000 IU/mL)
Number of subjects: 15
Study 15316509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11471088 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichiasis surgery
Number of subjects: 0
Study 11471088 — intervention group
Group type: COMPARATOR
Intervention: Untreated trichiasis
Number of subjects: 0
Study 9602202 — intervention group
Group type: COMPARATOR
Intervention: rhEPO 750 IU/kg/week (low-dose group)
Number of subjects: 184
Study 9602202 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO 1500 IU/kg/week (high-dose group)
Number of subjects: 184
Study 8030684 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (400 micrograms IV four times) and betamethasone (5 mg IM four times)
Number of subjects: 378
Study 8030684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 2810410 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin dosed at 1,200 mg every 12 hours
Number of subjects: 150
Study 2810410 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose amikacin (11 mg/kg)
Number of subjects: 150
Study 2810410 — intervention group
Group type: COMPARATOR
Intervention: 72-hour coverage
Number of subjects: 150
Study 931851 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (produced by rebreathing a gas mixture of 6% CO2 in air)
Number of subjects: 10
Study 931851 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive loading (rebreathing repeated during loading)
Number of subjects: 10
Study 931851 — intervention group
Group type: COMPARATOR
Intervention: Control (normal breathing without hypoxia)
Number of subjects: 10
Study 30016770 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA) 6-9 g/d for 12 weeks
Number of subjects: 0
Study 30016770 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA)
Number of subjects: 0
Study 28882152 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE intervention (portable play equipment, staff training, modified outdoor playtime)
Number of subjects: 195
Study 28882152 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 195
Study 26503196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-dose interferon alfa-2b (iHDI) 20 MIU/m2 administered intravenously 5 days a week for 4 weeks then repeated every 4 months
Number of subjects: 627
Study 26503196 — intervention group
Group type: COMPARATOR
Intervention: Standard high-dose interferon alfa-2b (HDI)
Number of subjects: 627
Study 23350686 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of parietal peritoneal layer (Group I)
Number of subjects: 110
Study 23350686 — intervention group
Group type: COMPARATOR
Intervention: Non-closure of parietal peritoneal layer (Control, Group II)
Number of subjects: 110
Study 21816683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention and exercise program
Number of subjects: 55
Study 21816683 — intervention group
Group type: COMPARATOR
Intervention: Lumbar fusion
Number of subjects: 55
Study 21816683 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 19030864 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD) therapy
Number of subjects: 34
Study 19030864 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonsteroidal anti-inflammatory drug, physical therapy, and therapeutic exercise program)
Number of subjects: 34
Study 19030864 — intervention group
Group type: COMPARATOR
Intervention: Both groups (MLD and control)
Number of subjects: 34
Study 19030864 — intervention group
Group type: EXPERIMENTAL
Intervention: MLD group
Number of subjects: 34
Study 16127567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg q.d.), tetracycline (500 mg q.i.d.), and furazolidone (200 mg t.i.d.) for 7 days (LTF; n = 52)
Number of subjects: 104
Study 16127567 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg b.i.d.) and amoxicillin (1 g b.i.d.) for 1 week, plus azithromycin (500 mg q.d.) for the first 3 days (LAAz; n = 52)
Number of subjects: 104
Study 16127567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg q.d.), tetracycline (500 mg q.i.d.), and furazolidone (200 mg t.i.d.) for 7 days (LTF)
Number of subjects: 104
Study 16127567 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg b.i.d.) and amoxicillin (1 g b.i.d.) for 1 week, plus azithromycin (500 mg q.d.) for the first 3 days (LAAz)
Number of subjects: 104
Study 14601489 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 30
Study 14601489 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 30
Study 10660161 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless aortic valve replacement (Freestyle, Toronto, n = 106)
Number of subjects: 180
Study 10660161 — intervention group
Group type: COMPARATOR
Intervention: Conventional biological aortic valve replacement (Carpentier‐Edwards, n = 74)
Number of subjects: 180
Study 8535227 — intervention group
Group type: COMPARATOR
Intervention: CHOP (doxorubicin)
Number of subjects: 115
Study 8535227 — intervention group
Group type: EXPERIMENTAL
Intervention: CIOP (idarubicin)
Number of subjects: 115
Study 1971641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (2 g)
Number of subjects: 12
Study 1971641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g)
Number of subjects: 12
Study 1971641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g)
Number of subjects: 12
Study 1971641 — intervention group
Group type: COMPARATOR
Intervention: Mueller-Hinton medium
Number of subjects: 12
Study 1971641 — intervention group
Group type: COMPARATOR
Intervention: Capsule medium
Number of subjects: 12
Study 1971641 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein binding effect
Number of subjects: 12
Study 474480 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemicellulose
Number of subjects: 8
Study 474480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose
Number of subjects: 8
Study 474480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin
Number of subjects: 8
Study 474480 — intervention group
Group type: COMPARATOR
Intervention: Basal diet alone
Number of subjects: 8
Study 31674644 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 1139
Study 31674644 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 1139
Study 31674644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ACTIVE) to Alendronate (ACTIVExtend)
Number of subjects: 1139
Study 31674644 — intervention group
Group type: COMPARATOR
Intervention: Abaloparatide to Alendronate
Number of subjects: 1139
Study 31674644 — intervention group
Group type: COMPARATOR
Intervention: Nonvertebral fractures and clinical fractures
Number of subjects: 1139
Study 30055002 — intervention group
Group type: EXPERIMENTAL
Intervention: School support intervention (school uniforms, school fees, and nurse visits)
Number of subjects: 835
Study 30055002 — intervention group
Group type: COMPARATOR
Intervention: Control group (no school support intervention)
Number of subjects: 835
Study 27386814 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based constraint-induced movement therapy (CIMT)
Number of subjects: 36
Study 27386814 — intervention group
Group type: COMPARATOR
Intervention: General game-based training
Number of subjects: 36
Study 27386814 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 36
Study 25847478 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP levels at baseline
Number of subjects: 296
Study 25847478 — intervention group
Group type: EXPERIMENTAL
Intervention: Each higher quartile of NT‐proBNP
Number of subjects: 296
Study 25847478 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted hazard ratio for NT‐proBNP after adding clinical AF burden
Number of subjects: 296
Study 23413135 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine aspartate 8 g combined with 200 mg of adenosine monophosphate (AA)
Number of subjects: 26
Study 23413135 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 26
Study 21198364 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional control scheme (Playstation 2)
Number of subjects: 0
Study 21198364 — intervention group
Group type: COMPARATOR
Intervention: More technologically advanced control scheme (Nintendo Wii)
Number of subjects: 0
Study 19954529 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 200 mg bid for 28 days (1-3 years old) or 400 mg bid for 28 days (4-11 years old)
Number of subjects: 60
Study 19954529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19954529 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 60
Study 19954529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Nitazoxanide and Placebo)
Number of subjects: 60
Study 17382741 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil for 6 weeks
Number of subjects: 281
Study 17382741 — intervention group
Group type: EXPERIMENTAL
Intervention: 5/20 mg tadalafil for 12 weeks
Number of subjects: 281
Study 17382741 — intervention group
Group type: EXPERIMENTAL
Intervention: 5/20 mg tadalafil with placebo run-in for 12 weeks
Number of subjects: 281
Study 17382741 — intervention group
Group type: EXPERIMENTAL
Intervention: 5/20 mg tadalafil for sexually active men with erectile dysfunction
Number of subjects: 281
Study 17382741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 15220016 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 749
Study 15220016 — intervention group
Group type: COMPARATOR
Intervention: NPH
Number of subjects: 749
Study 11450709 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g/day)
Number of subjects: 38
Study 11450709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11450709 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance (control group)
Number of subjects: 38
Study 9506326 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 15
Study 9506326 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 15
Study 8190206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment screening using the Information/Orientation Section of the Clifton Assessment Procedure with a cutoff point of 7.
Number of subjects: 2011
Study 8190206 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate analysis of associated factors for cognitive impairment.
Number of subjects: 2011
Study 8190206 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of associated factors for cognitive impairment.
Number of subjects: 2011
Study 3169109 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled gallopamil 10 mg
Number of subjects: 0
Study 3169109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diltiazem 120 mg
Number of subjects: 0
Study 3169109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31697371 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile neurofeedback for three months
Number of subjects: 41
Study 31697371 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile neurofeedback sessions (mean of 33.09 sessions, 10 minutes each)
Number of subjects: 41
Study 29984137 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention (4 educational workshops and 4 one-on-one visits over 4 months)
Number of subjects: 240
Study 29984137 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 educational workshop)
Number of subjects: 240
Study 29984137 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention
Number of subjects: 240
Study 28756068 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclaprim 0.8 mg/kg IV q12h
Number of subjects: 70
Study 28756068 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclaprim 1.2 mg/kg IV q8h
Number of subjects: 70
Study 28756068 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 1 g IV q12h
Number of subjects: 70
Study 26164092 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (Group A) including pedometers, website for step registration, physical activity on prescription, motivational interviewing (10 occasions), and group consultations (12 occasions)
Number of subjects: 310
Study 26164092 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer intervention (Group B) including pedometers and website for step registration
Number of subjects: 310
Study 26164092 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group C)
Number of subjects: 310
Study 22235792 — intervention group
Group type: EXPERIMENTAL
Intervention: CT group
Number of subjects: 11
Study 22235792 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT group
Number of subjects: 11
Study 22235792 — intervention group
Group type: COMPARATOR
Intervention: Comparison between CT and CBCT groups
Number of subjects: 11
Study 20069307 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25 mg bupivacaine alone
Number of subjects: 30
Study 20069307 — intervention group
Group type: COMPARATOR
Intervention: 3.75 mg bupivacaine, 25 mg mepivacaine and 0.0125 mg epinephrine
Number of subjects: 30
Study 20069307 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic painkillers
Number of subjects: 30
Study 20069307 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetics (bupivacaine and mixture)
Number of subjects: 30
Study 20069307 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infiltration
Number of subjects: 30
Study 18821691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg every 4 weeks for 24 weeks
Number of subjects: 1220
Study 18821691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1220
Study 18821691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus DMARDs
Number of subjects: 1220
Study 18821691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 1220
Study 18821691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1220
Study 16178659 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 120
Study 16178659 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis
Number of subjects: 120
Study 12439771 — intervention group
Group type: EXPERIMENTAL
Intervention: Living high-training low (LHTL)
Number of subjects: 21
Study 12439771 — intervention group
Group type: COMPARATOR
Intervention: Living low-training low (CONTROL)
Number of subjects: 21
Study 10353583 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 287
Study 10353583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (1600 microg four times daily)
Number of subjects: 287
Study 10353583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 7728627 — intervention group
Group type: EXPERIMENTAL
Intervention: Active chiropractic spinal manipulative treatment
Number of subjects: 31
Study 7728627 — intervention group
Group type: COMPARATOR
Intervention: Sham chiropractic spinal manipulative treatment
Number of subjects: 31
Study 7728627 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (active and sham)
Number of subjects: 31
Study 2045756 — intervention group
Group type: EXPERIMENTAL
Intervention: Italian coffee
Number of subjects: 15
Study 2045756 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg purified caffeine
Number of subjects: 15